Thalidomide analogs

Abstract

Thalidomide analogs that modulate tumor necrosis factor alpha (TNFα) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.

1 - 56 . (canceled) 
     
     
         57 . A composition comprising Compound I, or a salt thereof, and a pharmaceutically acceptable excipient. 
       
         
           
           
               
               
           
         
       
     
     
         58 . The pharmaceutical composition of  claim 57 , wherein said compound is in an amount sufficient to achieve a desired therapeutic effect. 
     
     
         59 . The pharmaceutical composition of  claim 57 , wherein said pharmaceutical composition is present in an amount sufficient to achieve a tissue concentration at the site of action that is at lease the same as a concentration that has been shown to be active in vitro, in vivo, or in tissue culture. 
     
     
         60 . The pharmaceutical composition of  claim 57 , wherein said pharmaceutical composition is in a form suitable for unit dose presentation to an individual in need thereof. 
     
     
         61 . The pharmaceutical composition of  claim 57 , wherein said pharmaceutical composition is in a form suitable for oral administration to an individual in need thereof. 
     
     
         62 . The pharmaceutical composition of  claim 57 , wherein said pharmaceutical composition is in a form suitable for parenteral administration to an individual in need thereof. 
     
     
         63 . The pharmaceutical composition of  claim 57 , wherein said pharmaceutical composition is in a form of a tablet or a capsule. 
     
     
         64 . The pharmaceutical composition of  claim 57 , wherein said pharmaceutical composition is in a form of a sterile aqueous or oleaginous solution. 
     
     
         65 . The pharmaceutical composition of  claim 57 , wherein said pharmaceutical composition is in the form of a tablet, capsule, powder, granule, lozenge, liquid, gel, or transdermal patch, wherein said pharmaceutical composition is in a form sufficient to administer to a subject in need thereof. 
     
     
         66 . The pharmaceutical composition of  claim 57 , wherein said pharmaceutically acceptable excipient is selected from a binding agent, a filler, a tableting lubricant, a disintegrant, a dispersing agent, a wetting agent, or combinations thereof. 
     
     
         67 . The pharmaceutical composition of  claim 57 , wherein said pharmaceutically acceptable excipient comprises a binding agent selected from syrup, acacia, gelatin, sorbitol, tragacanth, polyvinylpyrrolidone, and combinations thereof. 
     
     
         68 . The pharmaceutical composition of  claim 57 , wherein said pharmaceutically acceptable excipient comprises a filler selected from lactose, sugar, corn starch, calcium phosphate, sorbitol, glycine, or combinations thereof. 
     
     
         69 . The pharmaceutical composition of  claim 57 , wherein said pharmaceutically acceptable excipient comprises a tableting lubricant selected from magnesium stearate, talc, polyethylene glycol, silica, or combinations thereof. 
     
     
         70 . The pharmaceutical composition of  claim 57 , wherein said pharmaceutically acceptable excipient comprises a an agent selected from a carrier, a diluent, an adjuvant, or combinations thereof. 
     
     
         71 . The pharmaceutical composition of  claim 57 , wherein said pharmaceutical composition comprises a sustained release matrix. 
     
     
         72 . The pharmaceutical composition of  claim 57 , wherein said pharmaceutical composition comprises a biodegradable polymer. 
     
     
         73 . The pharmaceutical composition of  claim 57 , wherein said pharmaceutical composition comprises a second active agent. 
     
     
         74 . The pharmaceutical composition of  claim 57 , wherein said pharmaceutical composition comprises a second active agent, wherein said second active agent is selected from a TNF-α inhibitory agent, a chemotherapeutic agent, and combinations thereof. 
     
     
         75 . A kit comprising the compound of  claim 57  and instructions for intended use. 
     
     
         76 . A method of treating angiogenesis and/or tumor growth, comprising the step of administering the composition of  claim 57 .